# OriGene Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/origene-technologies

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.origene.com
- Total disclosed funding: $54M
- Latest round: Series D (Jun 9, 2015)
- Investors on record: 9

## About

OriGene Technologies, Inc. is a biotechnology company focused on providing innovative products and services in genomics and proteomics, primarily for research in molecular biology and cancer studies.Founded in 1995 and headquartered in Rockville, US, OriGene Technologies, Inc. specializes in developing and supplying genomic tools. The company has undergone various strategic adjustments to enhance its product offerings, but specific shifts are not documented. Patrick van Luijk founded the company, which has raised a total of USD 17.10 mn through investment rounds, including a recent Series D round led by Cathay Capital on June 1, 2016, involving additional investors like IDG Capital and Merieux Equity Partners.OriGene Technologies Inc. specializes in a diverse range of products and services primarily focused on genomics and proteomics. The company’s core offerings include validated antibodies, cDNA clones, lentiviral products, RNA interference (RNAi) tools, and a variety of recombinant proteins. These products are designed for use in research settings, particularly in the fields of molecular biology, cell biology, and cancer research. OriGene’s products facilitate advanced research applications such as gene expression analysis, protein purification, and functional studies in various biological contexts, serving a global clientele that includes academic research institutions, biotech firms, and pharmaceutical companies. The company’s products are marketed in key regions including North America, Europe, and parts of Asia.OriGene Technologies Inc. generates revenue through direct sales of its extensive product portfolio, which includes flagship offerings such as the GFAP Rabbit Polyclonal Antibody and various cDNA clones. Transactions typically occur through a business-to-business (B2B) model, with customers placing orders via the company's website or through direct partnerships. Products are available for purchase individually or as part of bundled solutions for enhanced value. Pricing structures are aligned with the specific needs of researchers and institutions. The company’s revenue is bolstered by repeat business from satisfied clients who utilize its products for ongoing research and development projects, ensuring a continuous flow of transactions within the scientific community.OriGene Technologies, Inc. plans to expand its product line with new innovations in genomic tools, aiming for launches in the coming years. The company is targeting market expansions into Asia and Europe by 2024, leveraging its recent funding of USD 17.10 mn from the Series D round to support these initiatives. The most recent deal on June 1, 2016, involved Merieux Equity Partners exiting its stake in the company.

## Funding rounds

- Series D, Jun 9, 2015, $17M — IDG Capital, Cathay Capital, Merieux Equity Partners
- Series C, Mar 21, 2013, $21M — Kleiner Perkins, Qiming Venture Partners, IDG Capital
- Series B, Mar 17, 2010, $16M — IDG Capital, Zero2IPO Ventures, President International Development Corporation, Strategic Business Innovator, Morningside Private Investors

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B, Series C, Series D
- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Series B
- President International Development Corporation — Series B
- Strategic Business Innovator (https://capitalatlas.ai/funds/strategic-business-innovator) — Series B
- Morningside Private Investors (https://capitalatlas.ai/funds/morningside-private-investors) — Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series C
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- Cathay Capital — Series D
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series D